New combo therapy tailors radiation for advanced nasopharyngeal cancer
NCT ID NCT07248696
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase II trial tests a personalized treatment for metastatic nasopharyngeal carcinoma. Patients first receive tislelizumab (immunotherapy) plus chemotherapy. Those who respond well may avoid or reduce radiotherapy, while others get targeted radiation. The study aims to see if this approach improves progression-free survival with fewer side effects. It involves 32 participants and is active but not recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tislelizumab (an immunotherapy drug) combined with gemcitabine and cisplatin chemotherapy, plus radiotherapy adjusted based on tumor response
What this could lead to
If successful, this approach could offer a more personalized treatment for metastatic nasopharyngeal carcinoma, potentially reducing the need for radiotherapy in patients who respond well to initial therapy.
What could go wrong
This is a small, early-phase trial with only 32 participants, so results may not apply to everyone. The combination therapy also carries risks of side effects from chemotherapy, immunotherapy, and radiation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CANCINOMA (NPC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, 400000, China